文献速递肿瘤 PET/CT核素与放射性配体治疗

[¹⁸F]AlF-NOTA-奥曲肽PET/CT在常规临床中的应用:288例神经内分泌肿瘤患者回顾性分析

Evaluation of [¹⁸F]AlF-NOTA-octreotide PET/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-23

该单中心回顾性分析纳入2023年3月至2024年1月间转诊行SSTR PET/CT的全部患者,共288例患者322次扫描,评估[¹⁸F]AlF-OC PET/CT在真实临床中的实施、生物分布与摄取特征。结果显示G3 NETs摄取充分(平均SUVmax 19.0),原发部位间摄取存在差异,胃NETs最高(53.3),肝(19.8)和骨(12.1)病灶摄取强。结论认为该示踪剂跨分级和器官部位摄取可靠,可作为⁶⁸Ga标记SSA的实用高通量替代。

要点

  • G3 NETs对[¹⁸F]AlF-OC摄取充分,平均SUVmax 19.0,与低级别NETs相当。
  • 原发部位摄取差异明显,胃NETs平均SUVmax最高(53.3),肺NETs为17.0。
  • 肝(19.8)和骨(12.1)病灶显示强示踪剂亲和力。

核心结论

  • 该大样本真实世界系列证实[¹⁸F]AlF-OC PET/CT是跨多种NEN亚型稳健且广泛适用的SSTR显像方法,包括前瞻性试验中代表性不足的肿瘤组。
  • 示踪剂跨分级和器官部位摄取可靠,支持其作为⁶⁸Ga标记SSA的实用高通量替代用于常规临床。

研究设计与样本

  • 单中心回顾性分析,纳入2023年3月至2024年1月间转诊行SSTR PET/CT的全部患者。
  • 共288例患者完成322次扫描,中位年龄64岁;病灶使用MIM 7.3.4半自动分割并定量评估。
  • 队列包括93例G1、84例G2、17例G3 NETs和3例神经内分泌癌(胃肠胰或未知原发),以及15例嗜铬细胞瘤/副神经节瘤和40例肺NETs;共评估4677个病灶。

主要发现

  • 平均注射活度为208.5 ± 73.6 MBq,平均摄取时间为121 ± 14 min。
  • G3 NETs摄取充分,平均SUVmax 19.0,与低级别NETs相当。
  • 原发部位间摄取存在差异,平均SUVmax最高见于胃(53.3)、乙状结肠(22.0)、直肠(20.5)、小肠(19.1)和胰腺NETs(17.1);肺NETs(17.0)摄取亦相当。
  • 肝(19.8)和骨(12.1)病灶显示强示踪剂亲和力。
  • 生理分布与已知表达SSTR的组织一致。

临床怎么用

  • 可将[¹⁸F]AlF-OC PET/CT用于常规SSTR显像,覆盖不同分级和原发部位的NEN亚型。
  • 判读时应考虑原发部位和器官部位间的摄取差异。

局限性

  • 为单中心回顾性分析,真实世界证据仍需进一步积累。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fluorine-18-labeled somatostatin receptor (SSTR) tracers are increasingly adopted as an alternative to generator-produced gallium-68 compounds for imaging neuroendocrine neoplasms (NENs). While [¹⁸F]AlF-NOTA-octreotide ([¹⁸F]AlF-OC) has shown comparable or even superior diagnostic performance in controlled clinical studies, real-world evidence remains limited, particularly for underrepresented NEN subtypes. This study evaluates the clinical implementation, biodistribution, and uptake characteristics of [¹⁸F]AlF-OC PET/CT in routine practice across the full NEN spectrum. MATERIALS AND METHODS: In this retrospective single-center analysis, all patients referred for SSTR PET/CT between March 2023 and January 2024 were included. Relevant clinical and demographic data, along with procedural details, were collected. Lesions were segmented semi-automatically using MIM version 7.3.4 and quantitatively assessed. Uptake patterns were analyzed according to tumor grade, primary tumor origin, organ site and clinical indication. RESULTS: A total of 322 scans were performed in 288 patients (median age 64 years). The cohort included 93 Grade 1 (G1), 84 G2, 17 G3 NETs and 3 neuroendocrine carcinomas of gastroenteropancreatic (GEP) or unknown origin, alongside 15 phaeochromocytoma/paraganglioma (PPGL) cases and 40 lung NETs. In total, 4,677 lesions were evaluated. Mean injected activity was 208.5 ± 73.6 MBq with an average uptake time of 121 ± 14 min. G3 NETs demonstrated sufficient uptake (mean SUVmax 19.0), comparable to low-grade NETs. Uptake varied by primary origin, with the highest mean SUVmax values observed in gastric (53.3), sigmoidal (22.0), rectal (20.5), small intestinal (19.1) and pancreatic NETs (17.1). Lung NETs (17.0) also have comparable uptake. Strong tracer avidity was observed in lesions within the liver (19.8) and bone (12.1). Physiological distribution was consistent with known SSTR-expressing tissues. CONCLUSION: This large real-world series confirms that [¹⁸F]AlF-OC PET/CT is a robust and broadly applicable SSTR imaging modality across diverse NEN subtypes, including tumor groups traditionally underrepresented in prospective trials of SSTR tracers. The tracer demonstrates reliable uptake across grades and organ sites, supporting its routine clinical use as a practical, high-throughput alternative to ⁶⁸Ga-labeled SSAs.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Leupe H, De Buyst SA, Dekervel J, et al. Evaluation of [¹⁸F]AlF-NOTA-octreotide PET/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patients. Eur J Nucl Med Mol Imaging. 2026. PMID: 42332192. doi:10.1007/s00259-026-08020-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。